| <P style="BACKGROUND: white; LINE-HEIGHT: 16.5pt"><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"> 关于美国食品和药物管理局（</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">FDA</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">）</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">“</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">尼莫地平胶囊忌静脉给药</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">”</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">的安全警示，现补充说明如下：</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial"> <SPAN lang=EN-US><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></SPAN></P>
<P style="BACKGROUND: white; LINE-HEIGHT: 16.5pt"><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"> 该安全警示中的</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">“</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">尼莫地平</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial">”</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial">特指在美国上市的尼莫地平胶囊，其不良反应是由错误给药方式所致，与尼莫地平药物无关。</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial"> <SPAN lang=EN-US><o:p></o:p></SPAN></SPAN></P>
<P style="BACKGROUND: white; LINE-HEIGHT: 16.5pt"><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"> 我国的尼莫地平制剂包括胶囊、片剂和注射液。其中尼莫地平注射液的有效性和安全性已获循证医学证实和指南推荐。尼莫地平注射液可安全用于治疗动脉瘤性蛛网膜下腔出血。</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial"><o:p></o:p></SPAN></P>
<P><SPAN style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: 宋体; mso-bidi-font-family: Arial; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA"> 延伸阅读：</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: #3e3e3e; FONT-FAMILY: Arial; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA; mso-fareast-font-family: 宋体"><A id=inner_doc_264496 title=FDA再次警告：尼莫地平胶囊切勿静脉给药 href="http://www.cmt.com.cn/yx_zx/xxgjb/xxgxw/201008/t20100805_264496.html" target=_blank _innerdocid="264496">FDA<SPAN lang=EN-US style="FONT-FAMILY: 宋体; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial"><SPAN lang=EN-US>再次警告：尼莫地平胶囊切勿静脉给药</SPAN></SPAN></A></SPAN></P> |
